BACKGROUND: The Response Evaluation Criteria in @entity5 (RECIST) guideline and Common Terminology Criteria for Adverse Events (CTCAE) criteria are used to assess chemotherapy efficiency and @entity137 in @entity1 with advanced @entity2 . However, no real-time, synchronous indicators that can evaluate chemotherapy outcomes are available. We wanted to evaluate @entity5 response and @entity137 in advanced @entity2 chemotherapy by using a novel synchronous strategy. RESULTS: We enrolled 316 @entity1 with advanced @entity2 who were treated with @entity900 -based therapy and followed up them for 3  years. Plasma was obtained before and after every chemotherapy cycle. We quantitative assayed total plasma DNA and methylation of the APC/ @entity15893 genes. Four parameters were assessed: methylation level before chemotherapy (meth0  h), methylation level 24  h after chemotherapy (meth24  h), total plasma DNA concentration before chemotherapy (DNA0  h), and total plasma DNA concentration 24  h after chemotherapy (DNA24  h). When meth24  h   >   meth0  h of at least one gene was used to predict @entity5 response, the correct prediction rate was 82.4  %. Additionally, @entity1 for whom DNA24  h/DNA0  h    <=   2 had mild @entity137 . Therefore, meth24  h   >   meth0  h and DNA24  h/DNA0  h    <=   2 were defined as criteria for better @entity5 response and fewer adverse events with a high correct prediction rate (84.7  %). CONCLUSIONS: Quantitative analysis of total plasma DNA and plasma APC/ @entity15893 methylation provide a real-time synchronous rapid monitoring indicator for therapeutic outcomes of advanced @entity2 , which could be a reference or supplementary guidelines in evaluating chemotherapy effects.

Real-time monitoring efficiency and @entity137 of chemotherapy in @entity1 with advanced XXXX .

@entity1 :: ('9606', 'Species') :: ['patients'] @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicity', 'toxicities'] @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor', 'Solid Tumors'] @entity2 :: ('MESH:D008175', 'Disease') :: ['lung cancer'] @entity900 :: ('MESH:D002945', 'Chemical') :: ['cisplatin'] @entity15893 :: ('11186', 'Gene') :: ['RASSF1A']
@entity2 :: (MESH:D008175,Disease) :: ['lung cancer']
